UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of January, 2021
Commission File Number: 001-39481
PainReform Ltd.
(Translation of registrant’s name into English)
60C Medinat Hayehudim
Herzliya, 4676670
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
PainReform Ltd.
Explanatory Note
On January 4, 2021, PainReform Ltd. (the “Company”) issued a press release titled: “PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110”.
A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
Investors and others should note that the Company may announce material information about its finances, product candidates, clinical trials and other matters to its investors using its website (https://www.painreform.com/) in addition to SEC filings, press releases, public conference calls and webcasts. The Company uses these channels to communicate with the Company’s shareholders and the public about the Company and other issues. It is possible that the information the Company posts on these channels could be deemed to be material information. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it posts on the Company’s website (referenced above) in addition to following its press releases, SEC filings, public conference calls, and webcasts.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: January 4, 2021 | PAINREFORM LTD. | |
By: | /s/ Ilan Hadar | |
Ilan Hadar | ||
Chief Executive Officer |
2